MP46-18 PATIENTS REPORT SATISFACTION/REGRET FOLLOWING FOCAL THERAPY FOR LOCALIZED PROSTATE CANCER: A PROSPECTIVE MULTICENTER EVALUATION

You have accessJournal of UrologyProstate Cancer: Localized: Ablative Therapy (MP46)1 Sep 2021MP46-18 PATIENTS REPORT SATISFACTION/REGRET FOLLOWING FOCAL THERAPY FOR LOCALIZED PROSTATE CANCER: A PROSPECTIVE MULTICENTER EVALUATION Alireza Ghoreifi, Masatomo Kaneko, Samuel Peretsman, Atsuko Iwata, Aliasger Shakir, Dordaneh Sugano, Jie Cai, Giovanni Cacciamani, Daniel Park, Osamu Ukimura, Duke Bahn, Inderbir Gill, and Andre Luis Abreu GhoreifiAlireza Ghoreifi More articles by this author , KanekoMasatomo Kaneko PeretsmanSamuel Peretsman IwataAtsuko Iwata ShakirAliasger Shakir SuganoDordaneh Sugano CaiJie Cai CacciamaniGiovanni Cacciamani ParkDaniel Park UkimuraOsamu Ukimura BahnDuke Bahn GillInderbir Gill AbreuAndre View All Author Informationhttps://doi.org/10.1097/JU.0000000000002067.18AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The objective is evaluate the treatment decision satisfaction regret among patients who underwent Focal (FT) for localized prostate cancer (PCa) with high-intensity focused ultrasound (HIFU) or cryoablation (CRYO). METHODS: We identified consecutive hemi-gland HIFU CRYO FT as primary PCa at three US institutions (IRB# HS-17-00749). survey validated questionnaires was mailed between February December 2020, including: 5-question Decision Regret Scale (DRS); International Prostate Symptom Score (IPSS); Index Erectile Function (IIEF-5). Potency defined IIEF-5 ≥ 18. score calculated based on 5 items DRS (Figure). Agreement each item measured a 5-point scale final converted 0-100 scale. 26. Multivariable logistic regression models were applied assess baseline post-FT predictors regret. Statistically significant if p<0.05. RESULTS: Out 236 patients, 143 (61%) responded (71/116 72/120 CRYO). Baseline characteristics similar responders no-responders. For responders, median (IQR) follow-up 43 (26-68) months. rate 19.6%, being 23.6% vs. 15.5% (OR 1.7, p=0.22). Figure shows details patients’ responses question. Higher PSA nadir 1.48, 95%CI 1.1-2, p=0.009) post FT, presence biopsy 3.98, 1.5-10.6, p=0.006), higher IPSS after 1.18, 1.01-1.04, p=0.03), de-novo impotence 6.67, 1.57-27, p=0.03) independent CONCLUSIONS: therapy well-accepted patients. nadir, biopsy, post-operative IPSS, are Source Funding: None © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e820-e821 Advertisement Copyright & Permissions© Inc.MetricsAuthor Information Expand Loading ...